# Carnitine for the Treatment of Atherosclerosis.

Study · id `cardio:ct-nct02117661` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02117661](<https://clinicaltrials.gov/study/NCT02117661>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02117661

Browse, organ or system: Heart; Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.

## Technical summary

Registry record NCT02117661. Randomized; double masking; primary purpose treatment. Start 2015-01 (actual); primary completion 2017-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 177 participants (enrolled count; ClinicalTrials.gov record NCT02117661, source copy `cardio:ctgov-nct02117661-2020-06-26`, retrieved 2026-10-26)
- Started: 2015-01 (actual) (ClinicalTrials.gov record NCT02117661, source copy `cardio:ctgov-nct02117661-2020-06-26`, retrieved 2026-10-26)
- Primary completion: 2017-07 (actual) (ClinicalTrials.gov record NCT02117661, source copy `cardio:ctgov-nct02117661-2020-06-26`, retrieved 2026-10-26)
- Completion: 2019-05 (actual) (ClinicalTrials.gov record NCT02117661, source copy `cardio:ctgov-nct02117661-2020-06-26`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02117661, source copy `cardio:ctgov-nct02117661-2020-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02117661-2020-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Carnitine for the Treatment of Atherosclerosis.
- Acronym: ECoM
- Condition: Metabolic Syndrome
- Intervention (Dietary supplement): L-carnitine capsules
- Intervention (Dietary supplement): Cellulose capsules
- Lead sponsor: Dr. Amer Johri
- Lead sponsor class: OTHER
- Collaborator: Heart and Stroke Foundation of Canada
- Collaborator class: OTHER
- Collaborator: Queen's University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as a collaborator: Heart and Stroke Foundation of Canada (`cardio:org-heart-and-stroke-foundation-of-canada`)
- Registry lists this organization as a collaborator: Queen's University (`cardio:org-queen-s-university`)

## Provenance

Content hash: 75fa21d432f3e23a8cf1506ffbbb8acb22e2b4c74cf289d00185c151e00b77bb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
